
Print

BRCA1/BRCA2 (Selected Variants)

Specific genetic variants in the BRCA1 and BRCA2 genes are associated with an increased risk of developing certain cancers, including breast cancer (in women and men) and ovarian cancer. These variants may also be associated with an increased risk for prostate cancer and certain other cancers. This test includes three genetic variants in the BRCA1 and BRCA2 genes that are most common in people of Ashkenazi Jewish descent.

play+2098074e48, you have a **greatly increased risk** of developing breast and ovarian cancer.

You have two of the three genetic variants we tested. Women with these variants have a much higher than average risk of developing breast and ovarian cancer. Risk for certain other cancers may also be increased.



One variant detected in the BRCA1 gene and one variant detected in the BRCA2 gene.

Please share your result with a healthcare professional. It is important to confirm this result in a clinical setting before taking any medical action.

How To Use This Test

This test does not diagnose cancer or any other health conditions and should not be used to make medical decisions. Results should be confirmed in a clinical setting before taking any medical action.

Please talk to a healthcare professional about additional testing to confirm this result and to better understand your potential cancer risks.

Review the BRCA1/BRCA2 (Selected Variants) tutorial

See Frequently Asked Questions

See Scientific Details for complete Indications for Use statement and full list of Warnings, Precautions, and Limitations

Intended Uses

- Tests for three specific genetic variants: the **185delAG** and **5382insC** variants in the BRCA1 gene and the **6174delT** variant in the BRCA2 gene. These variants are associated with an increased risk of developing certain cancers.
- Provides information on whether a person's genetic result is associated with an increased risk for breast and ovarian cancer and may be associated with an increased risk for prostate cancer and certain other cancers.

Limitations

- Does **not** test for all possible variants in the BRCA1 and BRCA2 genes. More than 1,000 variants in these genes are known to increase cancer risk. Only three of those variants are included in this test.
- Does **not** test for variants in other genes linked to hereditary cancers.
- Does **not** account for non-genetic factors, like environment and lifestyle, that influence overall cancer risk.
- The interpretation of your genetic result depends on the sex you reported in your account settings.

Important Ethnicities

- The variants included in this test are most commonly found in people of **Ashkenazi Jewish** descent.

You have a **greatly increased risk** of developing breast and ovarian cancer based on your result.

It is important to talk with a healthcare professional about options for screening and prevention. It is also important to confirm this result in a clinical setting before taking any medical action.



We detected the 185delAG variant in the BRCA1 gene and the 6174delT variant in the BRCA2 gene.

See Scientific Details

Estimates vary, but studies suggest that **45-85%** of women with a BRCA1 or BRCA2 variant develop breast cancer by age 70, and **up to 46%** develop ovarian cancer.

This is much higher than the risk for women in the general population. Women with a BRCA1 or BRCA2 variant who develop breast cancer also tend to do so at an earlier age, and they may develop ovarian cancer at an earlier age. They may also have an increased risk for certain other cancers. Women with both a BRCA1 and a BRCA2 variant are expected to have cancer risks at least as high as women with just one variant. Exact risks depend on family history and other factors.

See Scientific Details





Since you share DNA with your family members, they may also wish to learn more about their cancer risk.

Your parents, siblings, and children may also have one or both of the variants we detected. If you are thinking about sharing your results with family members, see this article for a discussion about things to consider before having the conversation. Genetic counselors can help your adult family members decide about genetic testing.

The BRCA2 variant we detected is also associated with a genetic condition called Fanconi anemia group D1.

Consider talking with a genetic counselor if you're thinking about having children. You can learn more about Fanconi anemia group D1 on our Frequently Asked Questions page.



There are things you can do to reduce your risk for breast and ovarian cancer.

Women with a BRCA1 or BRCA2 variant have a greatly increased risk of developing breast and ovarian cancer. But there are options to consider to help manage your risk for these cancers, so it's important to talk with your doctor about your result. Genetic counseling can also help you understand your results and options. For more information about what to think about and possible next steps, see this help article.



Know your family history

Women with your genetic result who have a family history of breast or ovarian cancer have a higher risk of developing cancer than women without a family history. By knowing your family history, a healthcare professional can better assess your risk.



Understand your options for screening and prevention

National guidelines recommend earlier and more frequent breast cancer screening for women with your genetic result, to help catch potential cancers at an early stage. However, there are currently no ovarian cancer screening tests that have been proven safe and effective. Your doctor can also explain options to reduce your risk for breast and ovarian cancer, which may include surgery or medication.



Maintain a healthy lifestyle

In general, maintaining a healthy weight, engaging in physical activity, limiting alcohol consumption, and avoiding smoking can reduce the risk for breast and ovarian cancer. However, more research is needed to fully understand the impact of these and other lifestyle factors on cancer risk in women with your genetic result.

It is important to confirm your result in a clinical setting before taking any medical action.

See Scientific Details for more information

About BRCA1/BRCA2-Related Cancers

BRCA1 and BRCA2 variants are associated with an increased risk for several different cancers, including breast cancer (in women and men) and ovarian cancer. Variants in these genes may also be associated with an increased risk for prostate cancer, pancreatic cancer, and melanoma. The risk estimates below apply to BRCA1 and BRCA2 variants in general, including the three variants in this report.

Lifetime cancer risks

- Women with a **BRCA1** variant have a 45-85% chance of developing breast cancer by age 70 and a 39-46% chance of developing ovarian cancer. They may also have an increased risk for pancreatic cancer.
- Women with a **BRCA2** variant have a 45-85% chance of developing breast cancer by age 70 and a 10-27% chance of developing ovarian cancer. They may also have an increased risk for pancreatic cancer and melanoma.
- Men with a BRCA1 or BRCA2 variant have an increased risk for male breast cancer and may have an increased risk for prostate cancer, pancreatic cancer, and melanoma.
- See Scientific Details to learn more about these risks

When these cancers develop

In general, the chances of developing cancer increase as a person gets older. However, women with a BRCA1 or BRCA2 variant have an increased risk for early-onset breast cancer (before age 45) and multiple breast cancers. Women with a BRCA1 variant may also develop ovarian cancer at an earlier age. Men with a BRCA1 or BRCA2 variant may develop earlier and more aggressive prostate cancer.

How common are BRCA1 and BRCA2 variants?

About 1 in 400 people in the general population has a BRCA1 or BRCA2 variant linked to hereditary breast and ovarian cancer, although most of those variants are not included in this report. Among people of Ashkenazi Jewish descent, about 1 in 40 has a variant (usually one of the three variants in this report).

Screening and prevention

Guidelines recommend that women with a BRCA1 or BRCA2 variant should be screened for breast cancer earlier and more often. However, there are currently no ovarian cancer screening tests that have been proven safe and effective. For women with a BRCA1 or BRCA2 variant, surgery and medication have been shown to be effective in reducing the risk of developing breast and ovarian cancer.

Men with a BRCA1 or BRCA2 variant should be screened for male breast cancer. Screening guidelines for prostate cancer vary.

Always consult with a healthcare professional before taking any medical action.

Read more at: National Cancer Institute* GeneReviews*

It is important to discuss this result with a healthcare professional.

It's important to consult with a healthcare professional to confirm your result and discuss options for cancer screening and prevention.

Print report

If you have questions about your results or how they might affect you or your family, a genetic counselor may be able to help.

Learn more

One of the variants we detected is also associated with a condition called Fanconi anemia group D1. If you're considering having children, a genetic counselor can help you understand if additional testing may be appropriate.

Learn more

See our Frequently Asked Questions for more information.

FAQs

©2018 23andMe, Inc.

BRCA1/BRCA2 (Selected Variants)

Scientific Details

Specific genetic variants in the BRCA1 and BRCA2 genes are associated with an increased risk of developing certain cancers, including breast cancer, ovarian cancer and men's breast cancer. These variants may also be associated an increased risk for prostate cancer and certain other cancers. This test includes three genetic variants in the BRCA1 and BRCA2 genes that are most common in people of Ashkenazi Jewish descent.

Genetic variants in the BRCA1 and BRCA2 genes are associated with an increased risk for certain hereditary cancers.

This report includes two variants in the BRCA1 gene and one variant in the BRCA2 gene. These three variants do not account for the majority of the BRCA1 and BRCA2 variants in the general population. More than 1,000 variants in these genes are known to increase cancer risk.

BRCA1 BRCA2

The BRCA1 gene contains instructions for making a protein that helps repair damaged DNA. The BRCA1 protein also helps control the process of cell division. Through both of these functions, the BRCA1 protein acts as a tumor suppressor, preventing cells from growing and dividing too rapidly. Certain variants in the BRCA1 gene disrupt the protein's function. This can lead to a buildup of DNA errors, and can cause normal cells to become cancer cells.

Read more at Genetics Home Reference.



You have two of the three genetic variants we tested.

Variants Detected | View All Tested Markers

Marker Tested	Genotype*		Additional Information
185delAG **Gene:** BRCA1 **Marker:** rs1060833395	(–,–) Variant copy from one of your parents	CT Typical copy from your other parent	**Biological explanation** **Typical vs. variant DNA sequence(s)** **Percent of 23andMe customers with variant** **References** [1, 12, 23, 36, 40, 42, 59, 60, 67, 97, 98, 103, 104, 114] Clinvar.
6174delT **Gene:** BRCA2 **Marker:** rs80359550	(–,–) Variant copy from one of your parents	T Typical copy from your other parent	**Biological explanation** **Typical vs. variant DNA sequence(s)** **Percent of 23andMe customers with variant** **References** [1, 12, 18, 23, 38, 40, 42, 43, 59, 82, 85, 97, 98, 102, 104, 114] Clinvar.

* The percent of 23andMe customers with a variant may not be representative of the general population.

This test cannot distinguish which copy you received from which parent. This test cannot determine whether multiple variants, if detected, were inherited from only one parent or from both parents. This may impact how these variants are passed down.

23andMe always reports genotypes based on the 'positive' strand of the human genome reference sequence (build 37). Other sources sometimes report genotypes using the opposite strand.

Test Interpretation

This report provides risk estimates for several cancers associated with BRCA1 and BRCA2 variants. In most cases, these estimates represent a general risk for individuals with any BRCA1 or BRCA2 variant, not the specific risk estimates associated with the three variants in this report. This test does not take into account non-genetic factors that influence a person's overall risk for these cancers.

Health Risk Estimates

Risk estimates are based on clinical studies that identify an association between a genotype and a health condition.

Numerical risk estimates are not available for people who have both a BRCA1 and a BRCA2 variant. An interpretation of "increased risk" is provided to people with this result. It is likely that their risk is at least as high as the risk for people with just one variant. More research is needed to understand the risk for people with this result.

For some cancers, numerical risk estimates are not available.


Consider talking to a healthcare professional if you have any concerns about your results.

References [30, 54, 59, 61, 111, 112]


Lifetime risk | **Risk by age**

The risk estimates shown below represent the cumulative risk of developing a given cancer by a certain age. For example, breast cancer risk by age 60 reflects the chances that a woman will develop breast cancer by the age of 60. Estimates for the general population were calculated by 23andMe based on observed cancers among women in the United States (U.S. Cancer Statistics Working Group, 2016). Estimates for people with a BRCA1 or BRCA2 variant are based on a study of women of Ashkenazi Jewish descent (King et al., 2003). These risk estimates are consistent with estimates for women of non-Ashkenazi descent (Kuchenbaecker et al., 2017).

Breast Cancer



Ovarian Cancer



See exact estimates by age

Other Factors

Many factors are known to influence the risk of developing breast and ovarian cancer in the general population. In women with your genetic result, the effects of most of these factors on cancer risk are not as well understood.

This is not a complete list of other factors. Except for age and family history, the effects of these factors on cancer risk in women with your genetic result are not as well understood.

People with multiple risk factors may have a higher risk of developing cancer.

Consult with a healthcare professional before making any major lifestyle changes.

Other Factors	References
Age In general, the chances of developing breast and ovarian cancer increase as women get older. However, women with a BRCA1 or BRCA2 variant have a higher risk of developing early-onset breast cancer (before the age of 45) and multiple breast cancers. Women with a BRCA1 variant may also develop ovarian cancer at an earlier age.	[11, 75, 87, 91, 111]
Family history Women with a BRCA1 or BRCA2 variant whose mothers or sisters have had breast or ovarian cancer are more likely to develop these cancers themselves. The risk is even greater in families with more than one affected family member. This increased risk is likely due to other shared genetic and non-genetic factors. A family history of pancreatic cancer or melanoma is also expected to increase a woman's risk for those cancers.	[11, 78]
Obesity In general, being overweight after menopause increases a women's chances of developing breast cancer. Weight gain during adulthood is also associated with an increased risk. In addition, obesity is associated with a higher risk for pancreatic cancer and may be associated with a higher risk for ovarian cancer. These increased risks may be due to differences in estrogen levels, insulin signaling, and inflammation in women who are overweight.	[2, 24, 34, 58, 63, 64, 74, 80, 113]
Reproductive history In general, women who started menstruating at a young age or who experience menopause at an older age have a higher risk of developing breast and ovarian cancer. Conversely, having children and breastfeeding are associated with a lower risk for these cancers. Scientists think that reproductive history affects breast and ovarian cancer risk by altering estrogen levels in the body. Factors that increase the amount of time a woman is exposed to estrogen are often associated with an increased risk for these cancers.	[3, 10, 28, 29, 32, 46, 63, 74, 100, 109]
Alcohol consumption In general, drinking alcohol increases the chances of developing breast cancer. The risk increases with greater alcohol consumption and does not seem to vary by type of alcohol consumed. Scientists think this increased risk may be due to changes in hormone levels caused by drinking alcohol. Alcohol consumption is not associated with an increased risk for ovarian cancer.	[2, 5, 21, 49, 95, 110]
Other genetic variants Other genetic variants seem to influence breast and ovarian cancer risk in women with a BRCA1 or BRCA2 variant. In combination, these other variants may increase or decrease a woman's risk for cancer compared to other women with a BRCA1 or BRCA2 variant. Scientists are still working to understand how these other variants modify cancer risk.	[75]
Hormone exposure Exposure to external sources of the hormones estrogen and progesterone affect the risk for breast and ovarian cancer in the general population. For example, certain types of hormone replacement therapy after menopause are associated with an increased risk for breast cancer. Current or recent use of hormone replacement therapy has also been associated with an increased risk for ovarian cancer. The use of oral contraceptives is linked to a decreased risk for ovarian cancer.	[2, 22, 25, 27, 63, 72]
Physical activity In general, women who regularly engage in physical activity have a lower risk of developing breast cancer than women who rarely or never do. In one study, women who walked more than seven hours per week had a lower risk for breast cancer compared to women who walked less than three hours per week. Moderate and vigorous exercise can also decrease breast cancer risk. The links between physical activity and ovarian and pancreatic cancer risk are not yet well understood.	[3, 39, 52, 69, 73, 77, 119]
Smoking In the general population, smoking may be associated with an increased risk of developing breast cancer and certain types of ovarian tumors. The strongest effect is observed in women who have smoked heavily for many years. Smoking is also a strong risk factor for pancreatic cancer, accounting for about 25% of all cases.	[3, 26, 45, 47, 68, 110]

Cancer Screening and Prevention Guidelines

Cancer screening can help detect certain cancers at an earlier stage, when they may be more treatable. The guidelines below apply to people with a BRCA1 or BRCA2 variant. These guidelines may help you and your doctor decide on the best screening and prevention plan for you.

Women
Women with a BRCA1 or BRCA2 variant should be screened for breast cancer earlier and more often than other women. However, there are currently no ovarian cancer screening tests that have been proven safe and effective. Women with a BRCA1 or BRCA2 variant may also consider preventive surgery or medication to reduce the risk for breast and ovarian cancer. No specific screening guidelines exist for pancreatic cancer and melanoma, but your doctor may have specific screening recommendations for you. Learn more about breast and ovarian cancer screening and prevention options from Facing Our Risk of Cancer Empowered.

Men
Men with a BRCA1 or BRCA2 variant should be screened for male breast cancer. Screening guidelines for prostate cancer vary. No specific screening guidelines exist for pancreatic cancer and melanoma, but your doctor may have specific screening recommendations for you. Learn more about screening for male breast cancer and prostate cancer from Facing Our Risk of Cancer Empowered.

Test Details

Indications for Use

The 23andMe Personal Genome Service (PGS) uses qualitative genotyping to detect select clinically relevant genetic variants. DNA isolated from human saliva collected from individuals 18 years with the Oragene·Dx model OGD500.001 for the purpose of reporting and interpreting genetic health risks, including the 23andMe PGS Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants). The 23andMe PGS Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants) is indicated for reporting of the 185delAG and 5382insC variants in the BRCA1 gene and the 6174delT variant in the BRCA2 gene. The report describes if a woman is at increased risk of developing breast and ovarian cancer, and if a man is at increased risk of developing breast cancer or may be at increased risk of developing prostate cancer. The three variants included in this report are most common in people of Ashkenazi Jewish descent and do not represent the majority of the BRCA1/BRCA2 variants in the general population. The test report does not describe a person's overall risk of developing any type of cancer, and the absence of a variant tested does not rule out the presence of other variants that may be cancer-related. This test is not a substitute for visits to a healthcare provider for recommended screenings or appropriate follow-up and should not be used to determine any treatments.

Special Considerations

- Genetic testing for BRCA1 and BRCA2 variants in the general population is not currently recommended by any healthcare professional organizations.
- Cancer risk associated with a BRCA1 or BRCA2 variant varies from person to person. Exact risk depends on family history and other factors.

Test Performance Summary

Clinical Performance [48, 50, 56, 57, 62, 71, 89, 93, 94, 108, 115, 116]

The variants included in this report represent a very small subset of all those associated with breast, ovarian, and prostate cancer. The three variants tested are associated with an increased risk of developing these cancers. However, some people who have these variants do not develop cancer. In addition, most cases of these cancers are not caused by inherited genetic cases.

- Approximately 5-10% of breast cancer cases, 10-15% of ovarian cancer cases, and 15-20% of male breast cancer cases are known to be caused by inherited variants in the BRCA1 and BRCA2 genes. This number is expected to be higher among individuals of Ashkenazi Jewish descent.
- The three variants in this report account for more than 90% of cancer-related BRCA1 and BRCA2 variants among people of Ashkenazi Jewish descent. These three variants account for a smaller proportion of cancer-related BRCA1 and BRCA2 variants found in people of other ethnicities.
- About 1 in 40 people of Ashkenazi Jewish descent is expected to have one of the three variants in this report. These three variants are much less common in people of other ethnicities. In 23andMe customers of other ethnicities, between 0% and 0.1% of individuals (up to 1 in 1,000) has one of the three variants in this report.

Analytical Performance

Accuracy was determined by comparing results from this test with results from sequencing. Greater than 99% of test results were correct. The 95% confidence interval was 83.9% to 100%. While unlikely, this test may provide false positive or false negative results. It is possible that the presence of certain mutations in your sample may interfere with the performance of this test. The effects of the interfering mutations on the performance of this test have not been studied. For more details on the analytical performance of this test, refer to the package insert.

Warnings, Precautions, and Limitations

- This test does not diagnose cancer or any other health conditions and cannot determine your overall risk of developing cancer in the future.
- This test should not be used to make medical decisions. Results should be confirmed in a clinical setting before taking any medical action.
- This test does not cover all variants that could increase risk for cancer.* The absence of a variant in this test does not rule out the presence of other genetic variants that may impact cancer risk.
- Other factors, such as environmental and lifestyle risk factors, may affect your risk of developing cancer. This test does not account for those factors, and does not test for variants in other genes linked to hereditary cancers.
- Your ethnicity may affect how relevant this test is for you.
- This test is intended to provide you with genetic information to inform conversations with your doctor or other healthcare professional.
- This device is not intended for prenatal testing.
- This test should not be used to assess the presence of genetic variants that may impact response to medications.
- This test is not intended to detect the presence of deterministic variants in autosomal dominant diseases or conditions.
- This test is not a substitute for visits to a healthcare professional for recommended screenings. Consult with a healthcare professional if you have any questions or concerns about your results or your current state of health.
- Some people feel a little anxious after getting genetic health risk results. This is normal. If you feel very anxious, you should speak to your doctor or a genetic counselor.

See the Package Insert for more details on use and performance of this test.

* Variants not included in this test may be rare, may not be established as genotyping problems, or may not pass our testing standards.

References

1. Abeliovich D et al. (1997). "The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women." Am J Hum Genet. 60(2):505-14.
2. Allen NE et al. (2009). "Moderate alcohol intake and cancer incidence in women." J Natl Cancer Inst. 101(5):296-305.
3. American Cancer Society. "Breast Cancer Facts & Figures 2017-2018." Atlanta: American Cancer Society, Inc. 2017.
4. American Cancer Society. "Breast Cancer in Men." Retrieved March 5, 2018, from https://www.cancer.org/cancer/breast-cancer-in-men.html.
5. American Cancer Society. "Breast Cancer." Retrieved March 5, 2018, from http://www.cancer.org/cancer/breast-cancer.html.
6. American Cancer Society. "Melanoma Skin Cancer." Retrieved March 5, 2018, from https://www.cancer.org/cancer/melanoma-skin-cancer.html.
7. American Cancer Society. "Ovarian Cancer." Retrieved March 5, 2018, from https://www.cancer.org/cancer/ovarian-cancer.html.
8. American Cancer Society. "Pancreatic Cancer." Retrieved March 5, 2018, from https://www.cancer.org/cancer/pancreatic-cancer.html.
9. American Cancer Society. "Prostate Cancer." Retrieved March 5, 2018, from https://www.cancer.org/cancer/prostate-cancer.html.
10. Anderson KN et al. (2014). "Reproductive risk factors and breast cancer subtypes: a review of the literature." Breast Cancer Res Treat. 144(1):1-10.

See all references

Change Log

Your report may occasionally be updated based on new information. This Change Log describes updates and revisions to this report.


Date	Change
April 9, 2018	BRCA1/BRCA2 (Selected Variants) report created.

23andMe
Receive up to $20 when you refer family and friends to 23andMe. Get started today.
©2019 23andMe, Inc. Terms of Service Privacy Help

See exact estimates by age

Breast cancer			
Risk by age	General population	BRCA1 variant	BRCA2 variant
30	<0.1%	3%	Not available
40	0.5%	21%	17%
50	2.0%	39%	34%
60	4.4%	58%	48%
70	7.9%	69%	74%

Ovarian cancer			
Risk by age	General population	BRCA1 variant	BRCA2 variant
30	<0.1%	Not available	Not available
40	0.1%	3%	2%
50	0.2%	21%	2%
60	0.4%	40%	6%
70	0.7%	46%	12%



variant

This is not a complete

References

BRCA1/BRCA2 (Selected Variants)

Frequently Asked Questions

Specific genetic variants in the BRCA1 and BRCA2 genes are associated with an increased risk of developing certain cancers, including breast cancer (in women and men) and ovarian cancer. These variants may also be associated with an increased risk for prostate cancer and certain other cancers. This test includes three genetic variants in the BRCA1 and BRCA2 genes that are most common in people of Ashkenazi Jewish descent.

BRCA1/BRCA2 (Selected Variants)

What does this test do?

What does this test not do?

The report says the variants included in this test are most common in people of Ashkenazi Jewish descent. What if I'm not of Ashkenazi Jewish descent?

Where can I learn more about cancer, support groups, and other resources?

My report says two variants were detected, one called 185delAG in the BRCA1 gene and one called 6174delT in the BRCA2 gene. What does this mean?

This means you have two of the three genetic variants we tested.

Women with a BRCA1 or BRCA2 variant have a greatly increased risk of developing breast cancer and ovarian cancer. They also have an increased risk for early-onset breast cancer (before age 45) and multiple breast cancers, and may also develop ovarian cancer at an earlier age. In addition, they may have an increased risk for pancreatic cancer and melanoma. The risks for women with both a BRCA1 and a BRCA2 variant are expected to be at least as high as the risks for women with just one variant.

However, this result does not mean you have developed or definitely will develop any of these cancers.

It is important to discuss this result with a healthcare professional. Results should be confirmed in a clinical setting before taking any medical action.

The BRCA2 variant we detected is also associated with a condition called Fanconi anemia group D1. Consider talking with a genetic counselor if you are thinking about having children. Learn more about genetic counseling.

Is this answer helpful? Yes No

What does greatly increased risk mean?

A "greatly increased risk" means that, based on your genetic result for this test, your chances of developing breast and ovarian cancer are much higher than average. Studies have found that 45-85% of women with a BRCA1 or BRCA2 variant develop breast cancer, compared to 12% for the general population. Similar studies have found that up to 46% of women with a BRCA1 or BRCA2 variant develop ovarian cancer, compared to 1-2% for the general population. The risks for women with both a BRCA1 and a BRCA2 variant are expected to be at least as high as the risks for women with just one variant. See Scientific Details for more information.

Your risk for pancreatic cancer and melanoma may also be higher than average. We cannot provide numerical risk estimates because risks for these cancers are not as well understood in people with your genetic result.

It is important to share this result with a healthcare professional.

Is this answer helpful? Yes No

My report says that women with a BRCA1 or BRCA2 variant have a 45-85% chance of developing breast cancer and up to a 46% chance of developing ovarian cancer. What do those percentages mean? And why is there such a large range?

A 45-85% chance of developing breast cancer means that, out of 100 women with a BRCA1 or BRCA2 variant, between 45 and 85 women will develop breast cancer by the age of 70.

Up to a 46% chance of developing ovarian cancer means that, out of 100 women with a BRCA1 or BRCA2 variant, up to 46 women will develop ovarian cancer by the age of 70.

The risks for women with both a BRCA1 and a BRCA2 variant are expected to be at least as high as the risks for women with just one variant.

Many studies have looked at variants in the BRCA1 and BRCA2 genes, and these studies report somewhat different risk estimates. Some of these differences may be due to other factors besides the BRCA1 and BRCA2 variants. For example, women with a BRCA1 or BRCA2 variant who have a family history of breast or ovarian cancer have a higher chance of developing these cancers themselves. Because the group of women included in each study is different, the risk estimates may be different as well.

Your exact risk of developing breast and ovarian cancer depends on many factors, including family history, lifestyle, and genetic factors not included in this test. A healthcare professional can help you get a more precise estimate of your risk.

Is this answer helpful? Yes No

What does it mean that the BRCA2 variant detected is associated with a condition called Fanconi anemia group D1?

This result does not mean that you have Fanconi anemia group D1. But your result may be relevant for your family.

Fanconi anemia group D1 is a condition characterized by birth defects, a decreased production of blood cells, and an increased risk for infections and cancer.

People with one copy of the BRCA2 variant we detected are carriers for Fanconi anemia group D1. They do not have the condition themselves, but they can pass a variant on to their children. A child must inherit a BRCA2 variant from each parent in order to have this condition. If your partner has a BRCA2 variant, each of your children may have a 25% chance of having Fanconi anemia group D1. Learn more about Fanconi anemia group D1 at Facing Our Risk of Cancer Empowered.

Is this answer helpful? Yes No

My report says two variants were detected, one called 185delAG in the BRCA1 gene and one called 6174delT in the BRCA2 gene. What are some things I could do?

This result is associated with a greatly increased risk of developing breast and ovarian cancer. Women with your result may also have an increased risk for pancreatic cancer and melanoma. It is important to share this result with a healthcare professional, such as a doctor or genetic counselor.

Professional guidelines recommend that women with your genetic result undergo more rigorous cancer screenings and consider certain medications and surgeries that can reduce the risk for cancer. Learn more about cancer screening and prevention.

For more information about what to think about and possible next steps, see this help article.

It is important to discuss your result with a healthcare professional. **Results should be confirmed in a clinical setting before taking any medical action.**

Is this answer helpful? Yes No

How could my result affect my family?

Since you share DNA with your family members, they may also be interested in your result. If you are thinking about talking to family members about your results, see this article for a discussion of things to consider before having the conversation.

Because you have two variants, it is expected that:

- Each of your children has a 75% chance of inheriting one or both variants from you.
- One or both of your parents has at least one of these variants.
- Each of your siblings may have one or both of these variants.

Because the variants we detected are associated with an increased cancer risk in both men and women, your adult family members may wish to learn more about their cancer risk. They can talk with a healthcare professional, such as a doctor or genetic counselor, to help them decide if genetic testing is right for them. Learn more about genetic counseling.

The BRCA2 variant we detected is also associated with a condition called Fanconi anemia group D1. People with one copy of this variant do not have Fanconi anemia group D1, but they could pass the variant on to their children. A child must inherit a BRCA2 variant from each parent in order to have this condition. If your partner also has a BRCA2 variant, each of your children may have a 25% chance of having Fanconi anemia group D1. A genetic counselor can help you determine if additional testing may be appropriate.

Is this answer helpful? Yes No

I have questions about my results. Who should I talk to?

It's normal to have questions or concerns after viewing this report. Some people feel anxious, upset, or worried about their risk or risk for their family members. Others simply want to understand their results better or talk to someone about what they can do. Genetic counselors can help. Genetic counselors are healthcare professionals with special training in genetics and genetic testing. Learn more about genetic counseling.

For more information about what to think about and possible next steps, see this help article.

Since you have a variant detected, it is also important to talk with a healthcare professional about your result and options.

Is this answer helpful? Yes No

Have more questions? Check out our Customer Care Help Center.

©2018 23andMe, Inc.